Literature DB >> 25901558

Results of the national lung cancer screening trial: where are we now?

Neel P Chudgar1, Peter R Bucciarelli1, Elizabeth M Jeffries1, Nabil P Rizk1, Bernard J Park1, Prasad S Adusumilli1, David R Jones2.   

Abstract

The National Lung Screening Trial was a large, multicenter, randomized controlled trial published in 2011. It found that annual screening with low-dose CT (LDCT) in a high-risk population was associated with a 20% reduction in lung cancer-specific mortality compared with conventional chest radiography. Several leading professional organizations have since put forth lung cancer screening guidelines that include the use of LDCT, largely on the basis of this study. Broad adoption of these screening recommendations, however, remains a challenge.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Low-dose CT; Lung cancer; NLST; Screening

Mesh:

Year:  2015        PMID: 25901558      PMCID: PMC4817217          DOI: 10.1016/j.thorsurg.2014.11.002

Source DB:  PubMed          Journal:  Thorac Surg Clin            Impact factor:   1.750


  39 in total

1.  Screening for lung cancer: moving into a new era.

Authors:  Frank C Detterbeck; Michael Unger
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

2.  When the average applies to no one: personalized decision making about potential benefits of lung cancer screening.

Authors:  Peter B Bach; Michael K Gould
Journal:  Ann Intern Med       Date:  2012-10-16       Impact factor: 25.391

3.  Results of the two incidence screenings in the National Lung Screening Trial.

Authors:  Denise R Aberle; Sarah DeMello; Christine D Berg; William C Black; Brenda Brewer; Timothy R Church; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; Constantine A Gatsonis; David S Gierada; Amanda Jain; Gordon C Jones; Irene Mahon; Pamela M Marcus; Joshua M Rathmell; JoRean Sicks
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

4.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

Review 5.  American Cancer Society lung cancer screening guidelines.

Authors:  Richard Wender; Elizabeth T H Fontham; Ermilo Barrera; Graham A Colditz; Timothy R Church; David S Ettinger; Ruth Etzioni; Christopher R Flowers; G Scott Gazelle; Douglas K Kelsey; Samuel J LaMonte; James S Michaelson; Kevin C Oeffinger; Ya-Chen Tina Shih; Daniel C Sullivan; William Travis; Louise Walter; Andrew M D Wolf; Otis W Brawley; Robert A Smith
Journal:  CA Cancer J Clin       Date:  2013-01-11       Impact factor: 508.702

6.  The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology.

Authors:  Paul F Pinsky; Timothy R Church; Grant Izmirlian; Barnett S Kramer
Journal:  Cancer       Date:  2013-08-26       Impact factor: 6.860

Review 7.  A systematic assessment of benefits and risks to guide breast cancer screening decisions.

Authors:  Lydia E Pace; Nancy L Keating
Journal:  JAMA       Date:  2014-04-02       Impact factor: 56.272

8.  Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

9.  Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force.

Authors:  Harry J de Koning; Rafael Meza; Sylvia K Plevritis; Kevin ten Haaf; Vidit N Munshi; Jihyoun Jeon; Saadet Ayca Erdogan; Chung Yin Kong; Summer S Han; Joost van Rosmalen; Sung Eun Choi; Paul F Pinsky; Amy Berrington de Gonzalez; Christine D Berg; William C Black; Martin C Tammemägi; William D Hazelton; Eric J Feuer; Pamela M McMahon
Journal:  Ann Intern Med       Date:  2014-03-04       Impact factor: 25.391

10.  A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions.

Authors:  Andrea C Villanti; Yiding Jiang; David B Abrams; Bruce S Pyenson
Journal:  PLoS One       Date:  2013-08-07       Impact factor: 3.240

View more
  6 in total

1.  Lobar or sublobar resections are safe procedures for management of early lung cancer.

Authors:  Alfonso Fiorelli; Immacolata Mauro; Gaetano Cicchitto; Aldo Prencipe; Mario Polverino; Vincenzo Giuseppe Di Crescenzo; Mario Santini
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Recent Advances in Exosomal Protein Detection Via Liquid Biopsy Biosensors for Cancer Screening, Diagnosis, and Prognosis.

Authors:  Chang Liu; Yunchen Yang; Yun Wu
Journal:  AAPS J       Date:  2018-03-08       Impact factor: 3.603

3.  How do organisational characteristics influence teamwork and service delivery in lung cancer diagnostic assessment programmes? A mixed-methods study.

Authors:  Gladys N Honein-AbouHaidar; Terri Stuart-McEwan; Tom Waddell; Alexandra Salvarrey; Jennifer Smylie; Mark J Dobrow; Melissa C Brouwers; Anna R Gagliardi
Journal:  BMJ Open       Date:  2017-02-23       Impact factor: 2.692

4.  Diagnostic accuracy of magnetic resonance imaging for the detection of pulmonary nodules simulated in a dedicated porcine chest phantom.

Authors:  Madeleine Bonert; Moritz Schneider; Olga Solyanik; Katharina Hellbach; David Bondesson; Thomas Gaass; Natalie Thaens; Jens Ricke; Thomas Benkert; Julien Dinkel
Journal:  PLoS One       Date:  2020-12-23       Impact factor: 3.240

5.  Non-invasive Detection of Exosomal MicroRNAs via Tethered Cationic Lipoplex Nanoparticles (tCLN) Biochip for Lung Cancer Early Detection.

Authors:  Chang Liu; Eric Kannisto; Guan Yu; Yunchen Yang; Mary E Reid; Santosh K Patnaik; Yun Wu
Journal:  Front Genet       Date:  2020-03-20       Impact factor: 4.599

6.  Downregulated microRNA-140-5p expression regulates apoptosis, migration and invasion of lung cancer cells by targeting zinc finger protein 800.

Authors:  Enqing Zhuo; Changqing Cai; Wenzhe Liu; Kunsong Li; Wenzhen Zhao
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.